ARCHIVES

ODAC Votes Against Cell Therapeutics Agent; Requires ChemGenex To Develop Diagnostic.

This article is from The Cancer Letter archive.

Vol. 36 No. 13 | April 9, 2010

Download PDF Visit The Full Archive

Related Articles

SWOG Opens Phase II Trial Of CuraGen’s HDAC Inhibitor For B-Cell Lymphoma

September 29, 2006

NCI Comprehensive Center List Omits Georgetown/Howard, Adds Arizona

June 1, 1990

“Optimal Criteria,” For Hospitals Treating Cancer Patients Developed; NCI Won’t Try Forcing Changes

November 1, 1974

Funding Opportunities: NCI Offers Funds To Develop, Validate Mouse Models

November 20, 1998

NCI Funded Over 4,500 Grants Last Year, Half Its $3B Budget.

January 19, 2001

Drug Shortages: Institutions Report Halting Enrollment in Clinical Trials

March 22, 2013